

Jung-Woo Chae

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/491322/publications.pdf>

Version: 2024-02-01

62
papers

507
citations

759233

12
h-index

794594

19
g-index

63
all docs

63
docs citations

63
times ranked

875
citing authors

#	ARTICLE	IF	CITATIONS
1	Chondroitin sulfate-hybridized zein nanoparticles for tumor-targeted delivery of docetaxel. <i>Carbohydrate Polymers</i> , 2021, 253, 117187.	10.2	41
2	Impact of TNF- α (rs1800629) and IL-6 (rs1800795) Polymorphisms on Cognitive Impairment in Asian Breast Cancer Patients. <i>PLoS ONE</i> , 2016, 11, e0164204.	2.5	36
3	Minimal Clinically Important Difference of the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) for Fatigue Worsening in Asian Breast Cancer Patients. <i>Journal of Pain and Symptom Management</i> , 2018, 55, 992-997.e2.	1.2	31
4	Pharmacokinetic characterization of decursinol derived from <i>Angelica gigas</i> Nakai in rats. <i>Xenobiotica</i> , 2011, 41, 895-902.	1.1	29
5	Population pharmacokinetics of moxifloxacin, cycloserine, p -aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 677-687.	2.5	28
6	Evaluation of plasma brain-derived neurotrophic factor levels and self-perceived cognitive impairment post-chemotherapy: a longitudinal study. <i>BMC Cancer</i> , 2017, 17, 867.	2.6	28
7	Effects of type 2 diabetes mellitus on the population pharmacokinetics of rifampin in tuberculosis patients. <i>Tuberculosis</i> , 2015, 95, 54-59.	1.9	27
8	Association of mitochondrial DNA content in peripheral blood with cancer-related fatigue and chemotherapy-related cognitive impairment in early-stage breast cancer patients: a prospective cohort study. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 713-721.	2.5	20
9	Application of Size and Maturation Functions to Population Pharmacokinetic Modeling of Pediatric Patients. <i>Pharmaceutics</i> , 2019, 11, 259.	4.5	19
10	Inhibition of Cytochrome P450 by Propolis in Human Liver Microsomes. <i>Toxicological Research</i> , 2016, 32, 207-213.	2.1	14
11	Development and validation of a sensitive LC-MS/MS method for the simultaneous quantitation of theophylline and its metabolites in rat plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 889-890, 44-49.	2.3	13
12	Physicochemical Characterization and Toxicity of Decursin and Their Derivatives from <i>Angelica gigas</i> . <i>Biological and Pharmaceutical Bulletin</i> , 2012, 35, 1084-1090.	1.4	12
13	Population PK/PD analysis of metformin using the signal transduction model. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 815-823.	2.4	12
14	Quantitative determination of duloxetine and its metabolite in rat plasma by HPLC-MS/MS. <i>Biomedical Chromatography</i> , 2013, 27, 953-955.	1.7	12
15	Biopharmaceutical characterization of decursin and their derivatives for drug discovery. <i>Drug Development and Industrial Pharmacy</i> , 2013, 39, 1523-1530.	2.0	11
16	Effect of decursin on the pharmacokinetics of theophylline and its metabolites in rats. <i>Journal of Ethnopharmacology</i> , 2012, 144, 248-254.	4.1	10
17	A simple pharmacokinetic model of alendronate developed using plasma concentration and urine excretion data from healthy men. <i>Drug Development and Industrial Pharmacy</i> , 2014, 40, 1325-1329.	2.0	10
18	BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 623-632.	2.3	9

#	ARTICLE	IF	CITATIONS
19	Psychometric properties and measurement equivalence of the Multidimensional Fatigue Syndrome Inventory- Short Form (MFSI-SF) amongst breast cancer and lymphoma patients in Singapore. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 20.	2.4	9
20	A mechanism-based pharmacokinetic model of fenofibrate for explaining increased drug absorption after food consumption. <i>BMC Pharmacology & Toxicology</i> , 2018, 19, 4.	2.4	9
21	Molecular design of anticancer drugs from marine fungi derivatives. <i>RSC Advances</i> , 2021, 11, 20173-20179.	3.6	9
22	Simultaneous determination of L-arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in the plasma of rodents with LC-MS/MS. <i>Arzneimittelforschung</i> , 2011, 61, 340-346.	0.4	8
23	Prediction of Methionine and Homocysteine levels in Zucker diabetic fatty (ZDF) rats as a T2DM animal model after consumption of a Methionine-rich diet. <i>Nutrition and Metabolism</i> , 2018, 15, 14.	3.0	7
24	Quantitative Determination of Amitriptyline and Its Metabolite in Rat Plasma by Liquid Chromatography-tandem Mass Spectrometry. <i>Bulletin of the Korean Chemical Society</i> , 2012, 33, 2163-2167.	1.9	7
25	Development of a pharmacokinetic/pharmacodynamic/disease progression model in NC/Nga mice for development of novel anti-atopic dermatitis drugs. <i>Xenobiotica</i> , 2014, 44, 975-987.	1.1	6
26	Effects of food intake on pharmacokinetics of mosapride in beagle dogs. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2015, 38, 497-499.	1.3	6
27	Performance comparison of first-order conditional estimation with interaction and Bayesian estimation methods for estimating the population parameters and its distribution from data sets with a low number of subjects. <i>BMC Medical Research Methodology</i> , 2017, 17, 154.	3.1	5
28	Chemotherapy-associated cognitive impairments in Korean cancer patients: Risk factors and functional outcome. <i>Psycho-Oncology</i> , 2018, 27, 1995-2001.	2.3	5
29	Optimizing Vancomycin Dosing in Chronic Kidney Disease by Deriving and Implementing a Web-Based Tool Using a Population Pharmacokinetics Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 641.	3.5	5
30	LC-MS/MS Assay Validation for a New Immune Modulator, JHL45, and its Major Metabolite in Plasma: Application to Pharmacokinetic Studies in Rats. <i>Bulletin of the Korean Chemical Society</i> , 2009, 30, 2631-2636.	1.9	5
31	Effect of decursinol angelate on the pharmacokinetics of theophylline and its metabolites in rats. <i>Food and Chemical Toxicology</i> , 2012, 50, 3666-3672.	3.6	4
32	Association of mitochondrial DNA content and displacement loop region sequence variations with cancer-related fatigue in breast cancer survivors receiving chemotherapy. <i>Mitochondrion</i> , 2020, 54, 65-71.	3.4	4
33	Development of a Pharmacokinetic Model Describing Neonatal Fc Receptor-Mediated Recycling of HL2351, a Novel Hybrid Fc-Fused Interleukin-1 Receptor Antagonist, to Optimize Dosage Regimen. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 584-595.	2.5	4
34	Effects of Carbamazepine and Phenytoin on Pharmacokinetics and Pharmacodynamics of Rivaroxaban. <i>Pharmaceutics</i> , 2020, 12, 1040.	4.5	4
35	Dose Optimization of Vancomycin Using a Mechanism-based Exposure-Response Model in Pediatric Infectious Disease Patients. <i>Clinical Therapeutics</i> , 2021, 43, 185-194.e16.	2.5	4
36	External evaluation of the predictive performance of seven population pharmacokinetic models for phenobarbital in neonates. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3878-3889.	2.4	4

#	ARTICLE	IF	CITATIONS
37	Development of a population pharmacokinetic model to describe olmesartan medoxomil/hydrochlorothiazide (20/12.5 mg) FDC tablet in male healthy South Korean subjects. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2014, 52, 676-683.	0.6	4
38	Bioequivalence Comparison of Two Formulations of Fixed-Dose Combination Glimepiride/Metformin (2/500 mg) Tablets in Healthy Volunteers. <i>Iranian Journal of Pharmaceutical Research</i> , 2014, 13, 365-71.	0.5	4
39	Model-Based Equivalent Dose Optimization to Develop New Donepezil Patch Formulation. <i>Pharmaceutics</i> , 2022, 14, 244.	4.5	4
40	A novel HPLC-MS/MS method for the simultaneous determination of astemizole and its major metabolite in dog or monkey plasma and application to pharmacokinetics. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 114, 121-126.	2.8	3
41	Chemotherapy drug concentrations in hair follicles: a potential biomarker to monitor the effectiveness of scalp cooling for chemotherapy-induced alopecia. <i>Supportive Care in Cancer</i> , 2018, 26, 3669-3670.	2.2	3
42	Clinical Evaluation of Acetaminophen-Galgeuntang Interaction Based on Population Approaches. <i>Pharmaceutics</i> , 2020, 12, 1182.	4.5	3
43	Effect of dissolved oxygen in alcoholic beverages and drinking water on alcohol elimination in humans. <i>Alcohol</i> , 2013, 47, 27-30.	1.7	2
44	Application of an Inter-Species Extrapolation Method for the Prediction of Drug Interactions between Propolis and Duloxetine in Humans. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1862.	4.1	2
45	Vancomycin Dosage and Its Association with Clinical Outcomes in Pediatric Patients with Gram-Positive Bacterial Infections. <i>Risk Management and Healthcare Policy</i> , 2020, Volume 13, 685-695.	2.5	2
46	Mitochondrial DNA content in peripheral blood as a biomarker for cancer-related fatigue in early-stage breast cancer patients: A prospective cohort study. <i>Journal of Clinical Oncology</i> , 2017, 35, 10018-10018.	1.6	2
47	The Effect of CYP2D6 Phenotypes on the Pharmacokinetics of Propafenone: A Systematic Review and Meta-Analysis. <i>Pharmaceutics</i> , 2022, 14, 1446.	4.5	2
48	Determination of influence of food intake after a single oral dose of mosapride in beagle dogs using nonlinear mixed effect modeling. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2015, 38, 590-595.	1.3	1
49	Determination of Matrine in Rat Plasma after Oral Administration of Novel Korean Herbal Medicine KIOM-MA128 and Application of PK. <i>Journal of Analytical Methods in Chemistry</i> , 2015, 2015, 1-6.	1.6	1
50	Population Pharmacokinetic Method to Predict Within-Subject Variability Using Single-Period Clinical Data. <i>Pharmaceutics</i> , 2021, 14, 114.	3.8	1
51	Pharmacokinetics of eperisone following oral administration in healthy Korean volunteers. <i>Biopharmaceutics and Drug Disposition</i> , 2021, 42, 94-102.	1.9	1
52	Clinical Benefits of Oral Anticoagulant Use in Cancer Patients at Increased Risk for Venous Thromboembolism per Khorana Index. <i>Risk Management and Healthcare Policy</i> , 2021, Volume 14, 1855-1867.	2.5	1
53	Evaluation for Potential Drug-Drug Interaction of MT921 Using In Vitro Studies and Physiologically-Based Pharmacokinetic Models. <i>Pharmaceutics</i> , 2021, 14, 654.	3.8	1
54	A web-based tool to predict chemotherapy-associated cognitive impairment during survivorship. <i>Journal of Clinical Oncology</i> , 2017, 35, e21609-e21609.	1.6	1

#	ARTICLE	IF	CITATIONS
55	Development and Validation of a Robust LC-MS/MS Method for the Simultaneous Quantification of Doxifluridine and its Two Metabolites in Beagle Dog Plasma. <i>Bulletin of the Korean Chemical Society</i> , 2010, 31, 2235-2241.	1.9	1
56	Development of a LC-MS/MS method for the determination of CKD-712 in rat plasma: Application to a pharmacokinetic study in rats. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1061-1062, 123-127.	2.3	0
57	Exposure-Response and Clinical Outcome Modeling of Inhaled Budesonide/Formoterol Combination in Asthma Patients. <i>Pharmaceutics</i> , 2020, 12, 336.	4.5	0
58	Compatibility Study between Physiologically Based Pharmacokinetic (PBPK) and Compartmental PK Model Using Lumping Method: Application to the Voriconazole Case. <i>Korean Journal of Clinical Pharmacy</i> , 2021, 31, 125-135.	0.3	0
59	Analysis of Pembrolizumab-induced Blood Glucose Level Change in Cancer Patients. <i>Korean Journal of Clinical Pharmacy</i> , 2021, 31, 237-246.	0.3	0
60	Simultaneous Determination of Olanzapine and its Major Metabolite N-Desmethyl Olanzapine in Rat Plasma by HPLC-MS/MS: Application of PK in Rat. <i>Bulletin of the Korean Chemical Society</i> , 2013, 34, 2567-2568.	1.9	0
61	Population Pharmacokinetic Modeling and Simulation of Afloqualone to Predict Steady-state Exposure Levels. <i>International Journal of Pharmacology</i> , 2018, 14, 276-284.	0.3	0
62	A simple time-to-event model with NONMEM featuring right-censoring. <i>Translational and Clinical Pharmacology</i> , 2022, 30, 75.	0.9	0